Bristol Myers Squibb, a big pharmaceutical company, is testing a new way to give their cancer medicine called Opdivo. Instead of using a needle that takes 30-50 minutes, they want to use a quick shot that only takes 3-5 minutes. They are making sure it works just as well and is safe for patients. If it does work, this new way could help many people with kidney cancer who have tried other treatments before. The company also bought some smaller companies to make their medicines better in the future. Read from source...

- The article is not informative enough about the phase III study of the subcutaneous formulation of nivolumab. It only mentions that it was the first to evaluate and demonstrate non-inferior pharmacokinetics, efficacy and consistent safety vis-a-vis its intravenous formulation (IV), but does not provide any details or data on how these outcomes were achieved.
- The article seems to downplay the importance of the subcutaneous formulation of nivolumab by focusing more on BMY's share price and industry decline, rather than on the potential benefits of the new formulation for patients and physicians.
- The article also does not mention any potential challenges or drawbacks of the subcutaneous formulation, such as side effects, cost, availability, or accessibility issues. It only presents the positive aspects of convenience and improved efficacy.
- The article mentions the failure of a late-stage study for Opdivo in combination with Yervoy, but does not provide any context or explanation for why this occurred, or how it affects the overall prospects of Opdido as a standalone treatment. It also does not mention any other ongoing or planned studies for Opdivo in different indications or combinations.
- The article seems to be overly optimistic about BMY's future growth and expansion, by highlighting the recent acquisitions of Mirati Therapeutics, Karuna Therapeutics, Inc., and RayzeBio, but not providing any evidence or analysis on how these will contribute to the company's bottom line or competitive advantage. It also does not address the challenges faced by BMY from generic competition and pricing pressures for its existing drugs, such as Revlimid and Eliquis.
- The article ends with a vague statement about BMY undertaking a strategic productivity initiative that will drive cost savings, but does not provide any details or projections on how much, when, or how these savings will be realized. It also does not mention any risks or challenges associated with this initiative, such as possible job losses, operational disruptions, or regulatory hurdles.